TPP-1

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

TPP-1  纯度: 98.04%

TPP-1 是 PD-1/PD-L1 相互作用的有效抑制剂。TPP-1 与 PD-L1 特异性高亲和力结合 (KD=95 nM)。动物模型中，TPP-1 通过再激活 T 细胞功能抑制肿瘤生长。

TPP-1

TPP-1 Chemical Structure

CAS No. : 2426685-25-6

规格 价格 是否有货 数量
25 mg ￥6000 In-stock
50 mg   询价  
100 mg   询价  

* Please select Quantity before adding items.

TPP-1 相关产品

•相关化合物库:

  • Bioactive Compound Library Plus
  • Peptide Library

生物活性

TPP-1 is a potent inhibitor of the PD-1/PD-L1 interaction. TPP-1 binds specifically to PD-L1 with a high affinity (KD=95 nM). TPP-1 inhibits human tumor growth in vivo via reactivating T-cell function[1].

体外研究
(In Vitro)

TPP-1 binds to PD-L1 with high affinity and blocks PD-1/PD-L1 interaction. The KD value of PD-L1 with TPP-1 peptide is about 95 nmol/L (around five times less than that with PD-1), The binding site of TPP-1 to PD-L1 is close to the interactive site of PD-1 and PD-L1[1].
TPP-1 (4 μM) reactivates T-cell functions, it induces IFNγ release significantly higher than control and SPP-1, and the TPP-1 group shows similar outcomes for cell proliferation[1].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.
体内研究
(In Vivo)

TPP-1 (subcutaneous injection; 4 mg/kg; every other day eight times; 32 days) inhibits tumor growth (compared with SPP-1 and control). The growth rate in TPP-1-treated mice is 56%. And when administered in the absence of T cells (control group), TPP-1 has no effect on the growth of the H460-luc tumors[1].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: 5 to 6-week-old female Balb/c nude mice  injected with H460 cells transfected with the plvx-puro/luciferase lentiviral vector[1]
Dosage: 4 mg/kg
Administration: Subcutaneous injection; 4 mg/kg; every other day eight times; 32days
Result: Inhibited the tumor growth in a tumor xenograft model via reactivating T-cell function. 

分子量

2488.67

Formula

C107H150N34O32S2
CAS 号

2426685-25-6
Sequence Shortening

SGQYASYHCWCWRDPGRSGGSK
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式
Powder -80°C 2 years
-20°C 1 year
In solvent -80°C 6 months
-20°C 1 month
溶解性数据
In Vitro: 

H2O : 50 mg/mL (20.09 mM; Need ultrasonic)

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 0.4018 mL 2.0091 mL 4.0182 mL
5 mM 0.0804 mL 0.4018 mL 0.8036 mL
10 mM 0.0402 mL 0.2009 mL 0.4018 mL

*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。
参考文献

  • [1]. Chunlin Li, et al. Peptide Blocking of PD-1/PD-L1 Interaction for Cancer Immunotherapy. Cancer Immunol Res. 2018 Feb;6(2):178-188.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务